Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes

Bone Marrow Transplantation, Published online: 27 September 2019; doi:10.1038/s41409-019-0699-6Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes

Source: Bone Marrow Transplantation - September 26, 2019 Category: Hematology Authors: Nicolas Stocker Myriam Labopin In ès Boussen Olivier Paccoud Agn ès Bonnin Florent Malard Corinne Amiel Jo ël Gozlan Giorgia Battipaglia R émy Duléry Federica Giannotti Annalisa Ruggeri B éatrice Gaugler Mohamad Mohty Eolia Brissot Source Type: research